Quell Therapeutics

Association, Biotechnology, Education, Health Care
Founded in 3/1/19
London, England, United Kingdom
For Profit

About Quell Therapeutics

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Company Metrics

  • Employees: 101-250
  • Monthly Visits: 5116
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue:
  • Total Funding: 240547512 USD
  • Last Funding: 156000000 USD (Series B)
  • Funding Status: Early Stage Venture

Technology Stack

Quell Therapeutics actively uses None products in their tech stack.

Market Presence

Industries: Association, Biotechnology, Education, Health Care

Headquarters: London, England, United Kingdom

Employees